omniture
Telix Pharma

Latest News

Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade

MELBOURNE, Australia, July 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-07-18 07:17 2022

Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals

MELBOURNE, Australia, July 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-07-11 08:21 1867

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2024-06-03 09:08 1559

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

* TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being de...

2024-05-31 07:19 2016

Telix Submits NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2024-05-27 07:21 1909

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

* CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based...

2024-05-21 07:58 1513

Q1 2024 Revenue and Business Update

MELBOURNE, Australia, April 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2024-04-17 15:05 2009

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

* FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging * Collabo...

2024-04-16 06:42 1382

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Te...

2024-03-27 05:59 933

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Lim...

2024-03-19 05:19 1864

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2024-03-12 05:44 1870

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-03-05 07:01 1717

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-02-27 05:55 8186

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-02-22 17:31 2299

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-02-08 06:11 2171

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

MELBOURNE, Australia, Jan. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2024-01-22 19:00 1592

Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2024-01-04 06:20 1894

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2023-12-19 05:44 1682

First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent

MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2023-12-11 19:40 1458

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2023-12-07 06:45 1650
12345 ... 7